A venture capital and growth equity firm is actively making investments in life sciences, and will invest as early as Series A and through growth transactions and is currently investing out of their second fund. New Rhein looks to invest between $10-30M per investment. The firm is looking for companies with clinical data and/or commercial products. The firm has a preference for funding companies that are repurposing existing approved technologies for new indications. The firm is willing to invest in therapeutics, medical device and diagnostics companies.
The firm has a primary focus on pharmaceuticals / therapeutics, and a secondary focus on medical devices. The firm is agnostic to indication.
The firm plays an active role in their portfolio companies. The firm will take a board seat with any company in which they invest.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Venture and Growth Equity Firm Invests Up to $30M in Therapeutics and Medical Devices, Open to All Types of Clinical Stage Technologies and Disease Areas
14 JulHot Investor Mandate: Global Company With Dedicated Early Stage Partnership Program Seeks to Work With and Strategically Invest in Diagnostics and Life Science Tools
14 JulA global leader in life sciences, diagnostics and applied chemical markets providing services, equipment, and support solutions to laboratories worldwide has an Early Stage Partnership Program through which the firm works with, and potentially invests in, early proof-of-concept to revenue stage companies that are a strategic fit to the firm’s core products and services. Apart from financial investing, the firm provides strategic support to the companies with whom they partner. While the firm will partner globally, it has primarily partnered with US and European companies to this point.
The firm partners with early stage companies that provide game-changing tools, technologies and applications to advance the Life Science Research, Clinical Research and Diagnostic markets. Within these markets, the firm is especially interested in the fields of Bioproduction Instrumentation, Cell & Gene Therapy Tools, Cellular Engineering and Analysis, Genomics, Lab Data Analytics & Informatics, Molecular Diagnostics and Sample Preparation. The firm is currently not considering therapeutics or medical devices. The firm has partnered with companies early in proof of concept and up to revenue-generating companies.
The firm’s Early Stage Partnership program will only invest in companies that are a strategic fit, but operates as a financial investor, separating any strategic partnerships from the financial investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Venture Capital Firm Invests Up to $20M in USA-Based Novel Therapeutics and Medical Devices Companies
14 JulA venture capital firm with multiple offices in the USA has assets under management of $1.6 billion. Since inception, the firm has raised five investment funds. The firm typically makes equity investments in U.S.-based companies, with portfolio companies located on both coasts and throughout the central part of the country. The firm will consider investing at all stages, with a focus on seed and early-stage investments, including founding companies. Investment size is up to $20 million throughout a portfolio company’s path to liquidity.
The firm is currently looking for new investment opportunities in the life science space, with a specific focus on biopharmaceuticals and therapeutic medical devices. The firm has invested in biopharmaceutical companies focused on developing drugs to treat enteral feeding intolerance and disorders that are driven by CD47-mediated signaling pathways, including leukemia, lymphoma, solid tumors, and pulmonary hypertension. In addition, the firm has invested in a medical device developing a minimally-invasive, catheter-based device to re-create valves in deep leg veins. The firm does not look at diagnostics, though may be interested in technology with real-time feedback for procedures.
The firm focuses on identifying and shaping early-stage life science companies in the series A/B rounds to create significant shareholder value. Because of its extensive operating expertise, the firm is able to help entrepreneurs achieve near-term objectives that position their companies for exit.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: VC Firm Invests Exclusively in Mental Health and Neurology, Interested in All Sectors of Life Sciences From Therapeutics to Digital Health
14 JulA venture capital firm based out of USA that invests exclusively in the mental health and neurology space. The firm’s biotech segment is interested in companies related to neuroscience and neurotherapeutics. The firm is raising their second fund right now, their first fund closed at over $22M. The firm looks to make Seed and Series A investments in the form of equity or convertible notes with a typical check size ranging from $500K-1.5M. The firm seeks to make investments in North America and Europe.
The firm is open to all 4 sectors as they relate to neurology. The firm is agnostic to subsector and indication with a particular focus on psychiatry and neurodegenerative diseases. The firm is open to pre-clinical and pre-prototype companies and is open to all 3 classes of medical devices with a stronger focus on 510K and PMA.
The firm is open to all types of management teams and is willing to lead or co-invest and will seek a board seat when leading.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
The Power of Your Pitch
7 JulBy Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
If capital launches the early-stage life science startup into space, then pitching is the match that lights the rocket. If only the process were as straightforward as lighting a simple match. Each step of an early-stage startup’s life takes careful planning, research, and strategy, and while Life Science Nation (LSN) has many resources to help them be successful, one of the most powerful are the tools designed to help them pitch directly to investors who are a fit for their product and stage of development.
Today’s free webinar, Maximizing the Power of Your Pitch will walk attendees through, not only the process of the RESI Boston Innovator’s Pitch Challenge (IPC), but also tried-and-true tools to help founders pitch powerfully. Not all pitches are created equal, and every audience may have different feedback, but over the past decade, LSN has seen trends come and go and has developed systems around what works. Join us at 2 PM EDT to learn more about pitching at RESI, fielding questions, and delivering a pitch that communicates your story well.
Interested in joining the IPC? Sign up by July 29 and save $300 on early bird rates! Applications are accepted on a rolling basis, so get yours in today!
Exhibit at RESI Boston
7 JulBy Candice He, Vice President of Business Development, Global Investment Strategist, LSN
RESI returns to Boston for its first in-person conference in over two years September 21-22, with an additional day of virtual partnering on September 23. Past in-person RESIs boasted a vibrant network of service providers, including CRO/CMOs, non-profits, suppliers, and professional services like law firms and banks. These service providers have played an essential role in the RESI ecosystem, and we are pleased to welcome them back with more offerings that include both onsite and digital formats to promote their services and connect them with early-stage startups who need them.
RESI’s unique value to its service providers is its dedication to early-stage companies in life science and healthcare. These startups have specific needs that make them ideal clients for a variety of providers. CRO/CMOs attend RESI to connect with preclinical therapeutics. Lab services with valuable R&D space, banks with life science-specific benefits, and law firms specializing in IP, term sheet negotiations, and more exhibit at RESI to connect with these founders who seek their services.
RESI exhibition includes a table for promotion and networking in the exhibit hall, as well as a dedicated webpage for additional marketing materials and connections with virtual attendees. Exhibitors also have their logo featured prominently on the RESI website, live agenda, program guide, and onsite signage. For $4K, the exhibitor package also includes a complimentary registration to participate in the partnering platform and attend all conference events. Interested in reaching a broad audience of early-stage entrepreneurs at RESI Boston? Check out our sponsorship brochure and contact us to learn more!

|
Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
|
|||
|
International
|
East Coast (USA) & China
|
Midwest (USA)
& Canada |
West Coast (USA)
|
![]() |
![]() |
![]() |
![]() |
|
Greg Mannix
Vice President International Business Development Book a Meeting Email Me |
Candice He
VP, Business Development & Global Investment Strategist Book a Meeting Email Me |
Antoinette Lowre
Manager of Business Development Book a Meeting Email Me |
Alexander Vassallo
Manager of Business Development, Entrepreneurial Education Lead Book a Meeting Email Me |
Summer of Savings Continues
7 JulBy Greg Mannix, Vice President International Business Development, General Manager Europe, LSN
The summer of savings continues with RESI Boston’s early bird rates available until July 29. RESI returns to Boston September 21-22, with an additional day of dedicated virtual partnering September 23. RESI attracts early-stage founders and CEOs of life science and healthcare startups seeking capital and licensing partners. These attendees are actively seeking funding, therefore, creating a valuable experience at an affordable rate is essential to their enthusiastic participation in RESI’s vibrant partnering and networking format.
Startups can save $300 with early bird rates when they register by July 29. Additionally, free webinars to enhance partnering and pitching, as well as how to make the most of the RESI experience are available throughout the summer. Sign up for a free webinar below and register for RESI Boston today and save!
July 7 | 2 PM EDT – Maximizing the Power of Your Pitch
Showcasing your company at events like the Innovator’s Pitch Challenge is an excellent opportunity to get visibility with investors and strategics. This workshop gives you tips from the application phase to the execution of the pitch and preparing for Q&A.
July 13 | 12 PM EDT – Fundraising Bootcamp: It All Starts with the Story
The most successful entrepreneurs are always the best storytellers. Finding a way to naturally formulate your company’s unique story and portraying this through multiple modalities whether it be a 1-minute elevator pitch or a 12-slide pitch deck is one of the most effective ways to get potential investors and partners on board with your value proposition. This bootcamp will cover the importance of entrepreneurial agency, finding your voice and developing a compelling narrative for the different players that will emerge along a deal chain, and language tools to refine your hook. Investors always bet on the team, not just the technology, and if every member of your startup can tell any strategic partner a consistent story of your company and technology, you are on the right track to building successful relationships.
July 20 | 1 PM EDT – Supporting Tech Hub Startups at RESI
This workshop is designed for tech hub organizations ranging from accelerators, incubators, non-profits, universities, tech transfer offices, and regional organizations who set up their early-stage life science startup constituents for success with their entrepreneurship and fundraising journey. It will showcase the tools and resources that LSN makes available for Tech Hubs to help their startup constituents who’ve raised less than $2M expand outreach from Regional to Global, build a target list of investors, and more.
July 26 | 11 AM EDT – Fundraising Bootcamp: Branding Your Company from Seed to Series B
Many companies have great science and a compelling project to tell investors about, but don’t have the right tools to communicate effectively. What are the elements of marketing collateral needed to efficiently fundraise in the early stages? This webinar will dive into this important subject and help you to build a powerful marketing collateral for your fundraise.
August 3 | 11 AM EDT – Maximizing the Power of Your Pitch
Showcasing your company at events like the Innovator’s Pitch Challenge is an excellent opportunity to get visibility with investors and strategics. This workshop gives you tips from the application phase to the execution of the pitch and preparing for Q&A.
August 17 | 1 PM EDT – Keys to Successful Partnering
Partnering events like the RESI conference series are a fundamental part of fundraising. They present a great opportunity to meet new potential investors and strategic partners but getting the meetings you want is competitive and difficult. What strategies have proven successful to get the most meetings? What can you do to stand out and have a better chance of catching the attention of investors? This webinar will address these and other important aspects of partnering.














